Ketamine therapy is primarily available to adults with treatment-resistant depression, certain other psychiatric conditions, or chronic pain that hasn’t responded to standard treatments. The specific criteria depend on whether you’re seeking the FDA-approved nasal spray (esketamine) or off-label IV ketamine infusions, which have different eligibility requirements and different paths to access.
The Core Requirement: Prior Treatment Failure
The single biggest factor in qualifying for ketamine therapy is having tried other treatments first. For depression, the most widely accepted threshold is inadequate response to at least two antidepressant medications taken at proper doses for a sufficient length of time. This is the clinical definition of treatment-resistant depression used by major guidelines worldwide, including those from the VA, the Canadian Network for Mood and Anxiety Disorders, and the European Medicines Agency. Some guidelines set the bar even higher, requiring failure of three different classes of antidepressants before considering a patient truly treatment-resistant.
“Adequate” matters here. If you stopped a medication early due to side effects or took it at a low dose, that may not count as a failed trial. Clinicians evaluating you for ketamine will want to confirm that previous medications were given a real chance to work.
Mental Health Conditions That May Qualify
Treatment-resistant depression is the condition most closely associated with ketamine therapy, but it’s not the only one. The American Psychiatric Nurses Association lists several groups as candidates for treatment:
- Adults with moderate to severe depression who haven’t responded to standard antidepressants
- People experiencing acute suicidal thoughts, where ketamine’s rapid onset (often hours rather than weeks) can be particularly valuable
- People with bipolar disorder, provided their mood is currently stabilized
- People with PTSD that hasn’t improved with conventional approaches
- People with personality disorders, as long as they can manage the infusion process and stay engaged in ongoing therapy
Ketamine’s ability to produce noticeable effects within hours or days, rather than the four to six weeks typical of most antidepressants, makes it especially relevant for people in acute crisis.
Chronic Pain Eligibility
Ketamine therapy is also used for chronic pain, particularly nerve pain that hasn’t responded to other treatments. Conditions that may qualify include neuropathic pain, fibromyalgia, complex regional pain syndrome (CRPS), and arthritis-related pain. The general criteria: you’ve had chronic pain for at least three months, it’s moderate to severe in intensity, and previous pain medications haven’t provided adequate relief.
The evidence is strongest for short-term pain reduction. IV ketamine has shown significant analgesic benefit in patients with refractory chronic pain, with higher doses generally producing greater relief. However, the effects tend to be temporary, which means repeat infusions are often part of the plan.
FDA-Approved Esketamine vs. Off-Label IV Ketamine
There are two distinct routes to ketamine-based treatment, and they come with different qualification standards.
Esketamine (brand name Spravato) is a nasal spray and the only form with FDA approval for depression. It’s specifically approved for treatment-resistant depression in adults and must be used alongside an oral antidepressant. The FDA requires it to be administered in a certified healthcare setting where you’re observed for at least two hours after each dose. You cannot take it home. This restriction exists because of risks related to sedation, dissociation, and potential for misuse.
IV ketamine infusions, on the other hand, are prescribed off-label. Because there’s no FDA-specific approval for psychiatric use of IV ketamine, eligibility criteria are set by individual clinics rather than federal regulators. This means requirements can vary from one provider to another, though most follow published clinical guidelines. Off-label IV ketamine clinics generally accept a broader range of conditions, including chronic pain and PTSD, that fall outside esketamine’s narrow FDA indication.
Who Does Not Qualify
Several physical and psychiatric conditions can disqualify you from ketamine therapy. On the physical side, the most common exclusions are:
- Uncontrolled high blood pressure. Ketamine temporarily raises blood pressure, so baseline readings above 140/90 mmHg typically mean treatment won’t proceed until blood pressure is managed. Readings above 180/110 mmHg represent a potential emergency in this context.
- Aneurysms or arteriovenous malformations, including in the brain, aorta, or peripheral blood vessels
- Recent heart attack or significant heart valve disease
- Moderate to severe heart failure
- History of bleeding in the brain
On the psychiatric side, the most significant concern is a history of psychosis. People who have experienced psychotic episodes may be more vulnerable to ketamine’s dissociative and perceptual effects. Active psychosis or poorly controlled schizophrenia is generally a firm exclusion. Active mania in bipolar disorder is also a disqualifier, though bipolar patients with stable mood may still be candidates.
Substance Use History
A history of substance use disorder complicates eligibility but doesn’t automatically rule you out. Ketamine has abuse potential, so clinics screen carefully for active substance use problems. Interestingly, research has explored ketamine as a treatment for addiction itself, with promising early results for alcohol, heroin, and cocaine dependence. But active, untreated substance use disorder is typically listed among exclusion criteria, particularly if you’re currently using dissociative drugs or have a history of ketamine misuse specifically.
The decision often comes down to clinical judgment. A history of substance use that’s now in remission is viewed very differently from active addiction.
Age Considerations
Ketamine has a long safety record across age groups as an anesthetic, with safe use documented in patients as young as 3 months old. For psychiatric applications, however, most clinics limit treatment to adults 18 and older. The FDA approval for esketamine specifies adults only. Some clinics treat older adolescents on a case-by-case basis, but pediatric psychiatric use of ketamine remains uncommon outside of research settings.
There’s no strict upper age limit, though older adults face higher rates of the cardiovascular conditions that can disqualify someone from treatment. Blood pressure monitoring before, during, and after each session is standard practice regardless of age.
What the Screening Process Looks Like
If you’re considering ketamine therapy, expect a thorough intake evaluation before your first session. Most clinics will ask for your complete psychiatric history, including every medication you’ve tried, at what dose, and for how long. This documentation of prior treatment failure is essential for establishing eligibility.
You’ll typically need a medical history review covering cardiovascular health, liver function, and any neurological conditions. Blood pressure is checked at baseline. Many clinics request records from your current psychiatrist or therapist, and some require an active referral. If you’re pursuing esketamine through insurance, your provider will need to document that you meet the treatment-resistant depression criteria with at least two failed antidepressant trials.
Insurance and Cost Realities
Insurance coverage differs sharply between the two forms of treatment. Esketamine, as an FDA-approved medication, is more likely to be covered by insurance, including Medicare, but your provider must document that you meet the treatment-resistant depression diagnosis. The claims process requires specific diagnostic codes tied to the FDA-approved indication.
IV ketamine infusions are rarely covered by insurance because they’re used off-label. Most patients pay out of pocket, with individual infusions typically ranging from $400 to $800. A standard initial course involves six infusions over two to three weeks, followed by maintenance sessions. This cost barrier is a practical qualification factor that many people encounter regardless of their clinical eligibility.